Skip to main content
Pharming Group N.V. logo

Pharming Group N.V. — Investor Relations & Filings

Ticker · PHARM ISIN · NL0010391025 LEI · 724500DCJ9MPG74JEH91 AS Manufacturing
Open in API
Filings indexed 799 across all filing types
Latest filing 2018-05-17 Interim / Quarterly Rep…
Country NL Netherlands
Listing AS PHARM

About Pharming Group N.V.

https://www.pharming.com/

Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company develops and commercializes an innovative portfolio of medicines to serve patients with unmet medical needs. Its portfolio includes protein replacement therapies, precision medicines, small molecules, and biologics.

Recent filings

Filing Released Lang Actions
Pharming Group Interim Report on Financial Results for the First Quarter 2018
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Pharming Group Interim Report on Financial Results for the First Quarter 2018'. It contains detailed financial statements (Consolidated Statement of Income), operational highlights, and management commentary for a period shorter than a full fiscal year (Q1 2018). It is not a mere announcement of a report, as it provides the actual financial data and analysis. Therefore, it is classified as an Interim/Quarterly Report. Q1 2018
2018-05-17 English
A global awareness day for a rare life-threatening condition: World HAEday, 16th May 2018
Regulatory Filings Classification · 95% confidence The document is a press release dated May 16, 2018, announcing support for World HAEday and providing commentary from the CEO regarding the company's involvement, product (RUCONEST®), and pipeline activities related to Hereditary Angioedema (HAE). It contains general company information, forward-looking statements, and contact details. This format is typical of an initial announcement of news or an event, rather than a comprehensive financial report (10-K, IR) or a formal transcript (CT). Since it is an announcement of company news and activities, it fits best under the general 'Regulatory Filings' (RNS) category as a press release, or potentially an 'Investor Presentation' (IP) if it were structured as slides, but given the narrative press release format, RNS is the most appropriate general classification for non-standard, timely corporate announcements that aren't explicitly covered by other codes like ER or DIV. It is not a formal financial report, earnings release, or management discussion.
2018-05-16 English
Pharming announces publication of 2017 Annual Report and invitation to Annual General Meeting of Shareholders
Report Publication Announcement Classification · 100% confidence The document explicitly announces the 'publication of 2017 Annual Report' and the 'invitation to Annual General Meeting of Shareholders'. It mentions that the 'Annual report, including its management report and 2017 financial statements, is available for download'. Since the document is an announcement about the release of the Annual Report and the AGM invitation, and it is relatively short (under 6,000 characters), it fits the criteria for a Report Publication Announcement (RPA) rather than the full 10-K report itself. The AGM invitation also points towards AGM-R, but the primary focus is the publication of the annual report, making RPA the most fitting classification based on the 'MENU VS MEAL' rule.
2018-04-11 English
Annual Report 2017
Annual Report Classification · 100% confidence The document is explicitly titled 'Annual Report 2017' for Pharming Group N.V. It contains comprehensive financial statements, management reports, auditor's reports, and operational highlights for the full fiscal year 2017. It meets the criteria for an Annual Report (10-K) as it provides a full yearly overview of company activity and financial performance. FY 2017
2018-03-29 English
Pharming enters the Euronext Amsterdam SmallCap-index (AScX)
Regulatory Filings Classification · 95% confidence The document is a press release dated March 15, 2018, announcing that Pharming Group N.V. has been included in the Euronext Amsterdam SmallCap-index (AScX). This type of announcement, which details a corporate event, index inclusion, or significant operational update that is not a full financial report (like 10-K or IR) or a specific transaction (like DIRS or POS), falls best under the general category of Regulatory Filings or a specific announcement type. Since it is a formal announcement of a corporate status change (index inclusion) and not a standard financial report, earnings release, or management change, it is best classified as a general Regulatory Filing (RNS) or potentially a Capital/Financing Update (CAP) due to the index inclusion's impact on capital access. However, RNS is the most appropriate fallback for non-standard, material corporate news announcements that don't fit the other specific codes. Given the content is a direct announcement of a corporate milestone, RNS is the most suitable general classification.
2018-03-15 English
Pharming announces issue of shares as majority of remaining warrants are exercised
Share Issue/Capital Change Classification · 99% confidence The document is a press release titled "Pharming announces issue of shares as majority of remaining warrants are exercised." It details the issuance of new shares due to the exercise of warrants and options, and provides a revised share capital structure table. This content directly relates to changes in the company's capital structure (share count, warrants, options). This aligns perfectly with the definition of 'Share Issue/Capital Change' (SHA). It is not a full Annual Report (10-K), an Earnings Release (ER), or a general Regulatory Filing (RNS), as it concerns a specific capital event.
2018-03-12 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.